Chaque ann\u00e9e, la conf\u00e9rence de l'American Society of Hematology (ASH) est l'occasion de pr\u00e9senter les derni\u00e8res recherches men\u00e9es dans le monde entier. Bien que les pr\u00e9sentations de la conf\u00e9rence ne fassent pas l'objet d'un examen par les pairs (contrairement aux articles de journaux), elles donnent l'occasion de voir ce qui se passe dans le pipeline de la recherche.<\/p>\n
Deux pr\u00e9sentations ont port\u00e9 sur la maladie de Waldenstrom et la Covid-19.<\/p>\n
https:\/\/ashpublications.org\/blood\/article\/138\/Supplement%201\/3791\/482596\/Patients-with-Multiple-Myeloma-on-Anti-CD38-or?searchresult=1<\/a> a fait \u00e9tat d'une \u00e9tude en cours en Gr\u00e8ce. Elle a compar\u00e9 la r\u00e9ponse en anticorps de patients atteints de la MW et du MM vaccin\u00e9s avec les vaccins Pfizer ou Astra-Zeneca \u00e0 une population similaire de t\u00e9moins sains.\u00a0 Citation cl\u00e9 :\u00a0<\/strong> \"Un traitement actif avec soit du rituximab, soit des inhibiteurs de la tyrosine kinase de Bruton (BTKI) s'est av\u00e9r\u00e9 \u00eatre un facteur pronostique ind\u00e9pendant pour une r\u00e9ponse suboptimale des anticorps apr\u00e8s la vaccination dans la MW (p<0,05)".<\/p>\n https:\/\/ashpublications.org\/blood\/article\/138\/Supplement%201\/816\/480036\/Efficacy-of-Vaccine-BNT162b2-Pfizer-BioNTech-in?searchresult=1<\/a> a fait \u00e9tat d'une \u00e9tude similaire, mais l\u00e9g\u00e8rement plus petite, men\u00e9e en Australie. Celle-ci n'a utilis\u00e9 que le vaccin Pfizer et a compar\u00e9 des patients atteints de lymphome MW et de lymphome folliculaire \u00e0 des t\u00e9moins sains.\u00a0 Citation cl\u00e9 :\u00a0<\/strong> \"Dans la MW, les patients sous BTKi avaient une r\u00e9ponse significativement r\u00e9duite par rapport aux patients na\u00effs de traitement. Cette m\u00eame r\u00e9duction n'a pas \u00e9t\u00e9 observ\u00e9e dans la cohorte chimioth\u00e9rapie-rituximab ...\"<\/p>\n Pour ceux qui souhaitent approfondir le sujet, vous pouvez consulter toutes les publications de la conf\u00e9rence de l'ASH qui traitent de la maladie de Waldenstrom sur ce lien : https:\/\/ashpublications.org\/search-results?q=Waldenstrom%27s&fl_IssueNo=Supplement+1&fl_Volume=138&fl_SiteID=1&page=1<\/a>.<\/p>","protected":false},"excerpt":{"rendered":" Every year, the American Society of Hematology (ASH) conference is an opportunity for the latest research from around the world to be presented.\u00a0 Although conference presentations do not go through peer review (unlike journal articles), they do provide an opportunity to look into what is coming down the research pipeline. Two presentations touched on Waldenstrom’s and Covid-19. https:\/\/ashpublications.org\/blood\/article\/138\/Supplement%201\/3791\/482596\/Patients-with-Multiple-Myeloma-on-Anti-CD38-or?searchresult=1 reported on an ongoing study from Greece.\u00a0 It compared the antibody response of WM and MM patients vaccinated with either the Pfizer or the Astra-Zeneca vaccines against a similar population of healthy controls.\u00a0 Key quote:\u00a0 “Active treatment with either rituximab or Bruton’s Tyrosine […]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[19,20],"tags":[],"class_list":["post-4781","post","type-post","status-publish","format-standard","hentry","category-covid19","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=4781"}],"version-history":[{"count":4,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4781\/revisions"}],"predecessor-version":[{"id":4785,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4781\/revisions\/4785"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=4781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=4781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=4781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}